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Abstract: A paucity of information is available on the activity of protease inhibitors (PI) in
chronically-infected monocyte-derived macrophages (MDM) and on the kinetics of viral-rebound
after PI removal in vitro. To fill this gap, the activity of different concentrations of amprenavir (AMP)
was evaluated in chronically-infected MDM by measuring p24-production every day up to 12 days
after drug administration and up to seven days after drug removal. Clinically-relevant concentrations
of AMP (4 and 20 µM) drastically decreased p24 amount released from chronically-infected MDM
from Day 2 up to Day 12 after drug administration. The kinetics of viral-rebound after AMP-removal
(4 and 20 µM) showed that, despite an initial increase, p24-production over time never reached the
level observed for untreated-MDM, suggesting a persistent intracellular drug activity. In line with
this, after AMP-removal, human immunodeficiency virus 1 (HIV-1) infectivity and intracellular the
p24/p55 ratio (reflecting virion-maturation) were remarkably lower than observed for untreated
MDM. Overall, AMP shows high efficacy in blocking HIV-1 replication in chronically-infected MDM,
persisting even after drug-removal. This highlights the role of protease inhibitors in preventing
the establishment of this important HIV-1 reservoir, thus reducing viral-dissemination in different
anatomical compartments.
Keywords: amprenavir; Human immunodeficiency virus; monocytes/macrophages; protease
inhibitors
1. Introduction
Human immunodeficiency virus 1 (HIV-1) establishes a chronic infection, which can lead to
severe immunodeficiency despite treatment with potent combined antiretroviral therapy (cART).
HIV-1 can evade immune response by several mechanisms, including the establishment of persistent
infection within different cell types, including memory or naive T lymphocytes and monocyte-derived
macrophages (MDM). In particular, monocyte-derived macrophages (MDM) represent an important
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HIV-1 cellular reservoir as they can survive to HIV-1 cytopathic effect for prolonged periods of time
(particularly microglia or alveolar macrophages) [1–8]. Furthermore, MDM can disseminate in different
anatomical compartments (including the brain), thus contributing to HIV-1 spread in the body of
an infected patient [9–11].
The morphogenesis of HIV-1 in MDM is different from that observed in CD4+ T lymphocytes.
Indeed, in MDM, HIV-1 can bud and accumulate within late endosomes [12–15]. These virion-laden
vesicles are presumably transported to the cell surface, and the virus is released from the cell surface
following cellular exocytosis pathways [13,14,16].
Among the different HIV-1 proteins, protease (PR) is fundamental for the proper maturation of
newly-produced virions as it cleaves gag and gag-pol polyprotein precursors to generate the single gag
and pol proteins [17–21], thus leading to the production of mature and infectious viral particles [22,23].
As a consequence of its activity, essential for virus infectivity, PR represents an important target for
the currently available cART. HIV-protease inhibitors prevent cleavage of gag and gag-pol polyprotein
precursors, thus determining the release of immature viral particles from infected cells [24]. In this
light, protease inhibitors (PIs) acting at a post-integrational step are so far, the only drug-class capable
of inhibiting HIV-1 replication in chronically-infected cells, including MDM.
So far, a paucity of information is available on the activity of protease inhibitors upon the release
of mature gag proteins from HIV-1-infected MDM. In particular, the following clinically-relevant points
have not been clearly elucidated yet: (i) is there a correlation between inhibition of the release of mature
virus gag proteins and the overall infectivity of virus particles released from chronically-infected cells;
(ii) the antiviral effect of protease inhibitors is sustained over time, even after drug removal.
Among the class of sulfonamide protease inhibitors, amprenavir (AMP) produces potent effect
against HIV-1 replication in CD4+ lymphocytes, with demonstrated activity in HIV-infected patients.
To provide a specific answer to the two above questions, we evaluated the characteristics and the
dynamic of HIV replication and infectivity in chronically-infected MDM treated with AMP in terms of
viral replication and infectivity rebound and in terms of gag-pol maturation and the morphology of
newly-produced virus, when treatment had been interrupted before.
2. Materials and Methods
2.1. Cells
Human primary MDM were prepared and purified as previously described [25–28]. Briefly,
MDM were obtained from the blood of healthy HIV-seronegative donors. Peripheral blood
mononuclear cells (PBMCs) were separated by Ficoll-Hypaque gradient centrifugation and seeded
in plastic 48-well plates (Costar, Cambridge, MA, USA) at a density of 1.8 × 106 cells/mL in RPMI
1640 (EuroClone, Milan, Italy) supplemented with 50 U/mL penicillin, 50 µg/mL streptomycin, 2 mM
L-glutamine and 20% heat-inactivated, mycoplasma- and endotoxin-free fetal calf serum (Corning,
NY, USA) (complete medium). Cell cultures were incubated in a humidified atmosphere with 5% CO2
at 37 ◦C. Non-adherent cells were removed 6 days after seeding by repeated gentle washing with
warmed RPMI 1640, leaving a monolayer of adherent cells, which were incubated in complete medium
as previously described [29–31]. Adherent cells obtained using this technique generally consisted of
>95% differentiated MDM (at cytofluorimetric analysis, more than 95% of cells were CD14+, CD4+,
CD3−). Experiments were led in at least 3 independent experiments. In each experiment, MDM
derived from a single donor.
2.2. Anti-HIV-1 Drugs
In this study, AMP was used as the prototype of a drug acting at the post-integrational step
and thus capable of inhibiting HIV-1 replication in the setting of a chronic infection. Stock solutions
from pure AMP powder were dissolved in dimethyl sulfoxide (DMSO; Calbiochem, La Jolla, CA,
USA) at a 20 µM solution and stored at −80 ◦C until used. In each experiment, the nucleoside reverse
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transcription inhibitor, zidovudine (AZT) was used as a prototype of a drug acting at a pre-integrational
step, thus ineffective at inhibiting HIV-1 replication in chronically-infected MDM.
2.3. HIV-1 Isolates
A monocytotropic isolate of HIV-1, HIV-1BaL, was used in all experiments involving primary
MDM. The characteristics and genomic sequence of this strain have been previously described [31,32].
The virus was expanded in human primary MDM, collected, filtered and stored at −80 ◦C before
use [28]. HIV-1BaL was used starting from a concentration of 35 ng (corresponding to 2.1 × 108
genomes) and from a 5000 Tissue Culture Infectious Dose (TCID)50/mL (as assessed by virus titration
in MDM).
2.4. Assessment of Antiviral Drug Activity in Chronically-Infected MDM
MDM were defined as being chronically infected when no new rounds of infection occurred in
cultures in vitro and the p24 production remained stable. For this purpose, MDM were challenged with
300 TCID50/mL of HIV-1BaL (in the absence of any drug) on Day 0. At the time-point in which chronic
infection was established, MDM were carefully washed at least twice to remove any virus present in
the supernatants, replenished with fresh complete medium and cultured under the same conditions as
described before. HIV-1 p24 release in supernatants was assessed every 3 days starting from Day 7.
On the basis of our previous experience [28,33,34], chronic infection is generally established 7–10 days
after viral challenge (some variation being detectable among different donors). In the experiments
described herein, drug treatment began 14 days after infection, when HIV-1 p24 production reached
a plateau [28].
Fourteen days after viral challenge (herein after called Day 0), MDM were carefully washed at
least twice to remove any virus present in the supernatants, replenished with fresh complete medium
containing various concentrations of AMP or AZT and cultured under the same conditions as described
before. Each drug concentration was run in triplicate or quadruplicate, while untreated controls were
run in sextuplicate. Starting from Day 0, all MDM-containing wells were washed (every 2 days)
and replenished with fresh medium containing the appropriate drug concentration, according to the
experimental protocol.
In selected experiments devoted to assess the duration of AMP activity following its removal,
the cells were extensively washed and the medium completely changed at Days 5 and 6 after the
beginning of treatment. Half of the wells were subsequently cultured without drug while the other
half were cultured in the presence of drug as before.
At the end of the experiment, MDM were harvested for electron microscopy (EM) and lysed for
Western blot analysis (see below).
Virus production was assessed at each time point by analysis of HIV-1 p24 production with
a commercially available Radio-Immuno-Assay (RIA) (DuPont, Wilmington, DE, USA).
2.5. Virus Infectivity
Infectivity of virus particles produced by HIV-1-infected MDM was evaluated on MDM obtained
from a different seronegative donor exposed to serial dilution of supernatants from drug-treated
or non-treated HIV-1-infected MDM. The infectivity was assessed after 21 days (Day 14 of drug
treatment, Day 7 after drug removal) of infection by measuring the p24 production. The TCID50/mL
was calculated according to the Reed and Muench method.
2.6. Ultrastructural Study
Cells for electron microscopy were fixed in 2.5% glutaraldehyde (Serva, Heidelberg, Germany,
F.R.G.; No. 23114) in phosphate buffered saline (PBS) pH 7.4 at 4 ◦C. Subsequently, MDM were
washed twice in PBS and then fixed in osmium tetroxide 1.33% for 2 h at 4 ◦C. After several washes
in PBS, the cells were dehydrated in graded alcohol, transferred into toluene and embedded in Epon
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812 resin, then allowed to polymerize in a dry oven at 60 ◦C for 24 h. Thin sections were examined on
an Axioscope microscope (Zeiss, Jena, Germany). Ultra-thin sections were cut on a Richert microtome
using a diamond knife, were stained with uranyl-acetate-lead-hydroxide and evaluated on a Philips
electron microscope CM10 (Philips, Endhoven, The Netherlands).
Intracellular p24 levels’ determination: HIV-1 chronically-infected MDM were removed from
incubation and washed twice with 2 mL of cold PBS, then the supernatants were removed and stored
at −80 ◦C for intracellular p24 titration.
2.7. Western Blotting of Cell Cultures
Cells were lysed in ice cold Radio-Immunoprecipitation Assay (RIPA) buffer (50 mM Tris-HCl,
pH 7.4; 250 mM NaCl; 50 mM NaF; 0.15% Triton X-100) containing a protease inhibitor cocktail
(1 mM phenylmethylsulfonyl fluoride; 10 µg/mL pepstatin; 10 µg/mL leupeptin) and incubated for
20 min at 4 ◦C. Cell lysates were centrifuged at 13,000 rpm for 10 min at 4 ◦C. Protein concentrations
were determined by the bicinchoninic acid (BCA) protein assay (Thermofisher, Monza, Italy).
Cell lysates containing 10 µg protein mixed and equal volume of 2× Laemmli buffer were boiled
for 5 min, separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
nitrocellulose membranes.
The membranes were blocked overnight with 5% bovine serum albumin (BSA) in tris buffered
saline (TBS)-tween buffer and incubated overnight using the broadly-reactive mouse monoclonal
antibody AG3.0, for 1 h at room temperature in TBS-tween buffer and 1% BSA, recognizing HIV-1
p24, p55 and p150 (gag-pol) (NIH AIDS Research, Rockville, MD, USA). Then, membranes were
treated with the corresponding horseradish perroxidase (HRP)-conjugated secondary antibody,
and immunoreactivity was detected with an Immun-Star HRP Chemiluminescent Kit (Amersham,
Piscataway, NJ, USA). For the p24/p55 ratio quantification, the bands on the films were first scanned
by the Epson software program, and then, the images were processed through the Scion Image analysis
program (Houston, TX, USA) for the IBM PC based on the NIH Image on the Macintosh platform.
2.8. Statistics
Differences were considered statistically significant at p ≤ 0.05. Statistical analyses were carried
out with SigmaStat 3.0 (Jandel Scientific, San Rafael, CA, USA).
3. Results
3.1. Impact of Amprenavir in Inhibiting HIV-1 Replication in MDM
We have previously demonstrated that AMP can substantially inhibit HIV-1 replication in
acutely-infected MDM (treated before HIV-1 challenge) [29]. Thus, the first step of this study was
to evaluate the antiviral activity of AMP in HIV-1 chronically-infected MDM. Viral replication in
HIV-1-infected MDM treated with several doses of AMP was assessed by measuring p24 released in
culture supernatant at 10 days after infection (time point at which there is a stable viral production).
The highest concentrations of AMP (4 and 20 µM) determined a drastic decrease in p24 amount in
the supernatant from Day 2 after drug treatment (corresponding to 12 days after infection) (Figure 1)
Then, the p24 amount remained stable up to Day 12 after drug treatment (p24 decrease compared
to untreated control: 73.2% for AMP 4 µM and 91% for AMP 20 µM). AZT at 20 µM was completely
ineffective at blocking p24 release in chronically-infected MDM (Figure 1).
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in the extracellular compartment were more abundant than those present in cytoplasmic vacuoles (the 
latter a phenomenon typical only of HIV-infected MDM, but not CD4+ lymphocytes with a classical 
morphology). Conversely, in AMP-treated HIV-1-infected MDM, electron microscopy highlighted the 
presence of several immature viral particles inside cytoplasmatic vacuoles lacking the electron dense 
conic-shaped core, with altered organization of the envelope (Figure 2B). 
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Figure 1. Kinetics of human immunodeficiency virus 1 (HIV-1) p24 gag Ag production in supernatants
from HIV-1 chronically-infected monocyte-derived macrophages (MDM) treated with different doses
of amprenavir (AMP). On Day 10 after infection, when HIV-1 infection becomes chronic, the drug was
added to chronically-infected MD . The figure reports data from a si gle experiment (each time point
run at least in triplicate), which is representative of hree different experim nts.
By elec ron microscopy, in untreated HIV-1-infected MDM, viral particles had the typical electron
dense conic-shaped core, indicating a proper maturation (Figure 2A). In addition, viral particles
released in the extra ellular compar ment were more abundant than those present in cytoplasmic
va uoles (the latter a phenomenon typical only of HIV-infected MDM, but not CD4+ lymphocyt s
with a classical morphology). Conversely, in AMP-treated HIV-1-infected MDM, electron microscopy
highlighted the presence of several immature viral particles inside cytoplasmatic vacuoles lacking the
electron dense conic-shaped core, with altered organization of the envelope (Figure 2B).
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Figure 2. Photographs of electron microscopy representing: (A) viral particles contained in cytoplasmatic
vacuoles in untreated HIV-1-infected macrophage; (B) immature virus particles contained in cytoplasmatic
vacuoles in AMP-treated HIV-1-infected MDM.
3.2. Kinetics of Viral Rebound after Amprenavir Removal
The second step of this study was to investigate the kinetics of viral rebound after AMP removal
in HIV-1 chronically-infected MDM. To achieve this goal, p24 production in HIV-1-infected MDM
was measured at different time points after drug removal. AMP was removed after seven days of
treatment. At 12 h after drug removal, there was an increase in p24 production for all concentrations of
AMP tested. As expected, for the lowest concentration of AMP (0.16 µM), p24 production over time
reached levels observed for untreated MDM (Figure 3).
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Figure 3. Kinetics of HIV-1 p24 rebound after AMP removal. HIV-1 p24 was measured in
culture supernatants at 12, 24, 48 and 72 h after drug-removal from the supernatants of HIV-1
chronically-infected MDM. TI: treatment-interruption.
A different behavior was observed for the highest concentrations of AMP. Indeed, after an initial
increase, p24 production over time never reached the level observed for untreated MDM
(Figures 3 and 4). No ably, for AMP 20 µM, p24 production at th e and seven days after drug
removal showed a 46% and 49% reduction compared to untreated MDM, respectively (Figure 4A).
Similarly, for AMP 4 µM p24 production at three and seven days after drug removal showed a 26% and
17% reduction compared to untreated MDM, respectively (Figure 4A). Overall, these results suggest
a persistent intracellular activity despite drug removal from cell culture.
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Figure 4. (A) Reduction of HIV-1 p24 production at three and seven days after drug removal in
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To confirm this hypothesis, the infectivity of viral particles released from infected MDM in which
AMP was removed was compared with the infectivity of viral particles released from infected MDM
in which AMP was maintained, as well as from untreated MDM. As expected, the highest titer was
observed for untreated MDM. Interestingly, a significant decrease in TCID50/mL was observed not only
for drug-treated MDM, but also for those in which AMP was removed (Figure 4B).
In order to better explain the decreased HIV-1 infectivity, we evaluated p24 maturation in
chronically-infected MDM after AMP removal. In particular, we measured the intracellular HIV-1
p24/p55 ratio in HIV-1-infected MDM at different days after drug removal. p55 is a p24 precursor;
thus, the p24/p55 ratio can be considered a parameter to measure the maturation of the capsid. In all
three experimental conditions, the p24/p55 ratio showed a drastic decrease, indicating an impairment
in the maturation of the capsid despite the removal of the drug (Figure 5).Viruses 2017, 9, 277 9 of 13 
 
 
Figure 5. (A) Effects of AMP removal on p24 maturation in HIV-1 BaL chronically-infected MDM. p24 
maturation was expressed as the ratio of p24 amount on p55 amount in cell lysates. p24 and p55 
amounts were determined by ELISA; (B) western blot analysis showing p24 and p55 amount detected 
in cell lysates from chronically-infected macrophages. * Indicates the removal of AMP. In (A,B), the 
following experimental conditions were tested: Group 1, 18th day infection and 7th day treatment; 
Group 2, 18.5th day infection and 7.5th day treatment; Group 3, 19th day infection and 8th day 
treatment. HIV-1 BaL refers to an HIV-1 strain isolated from alveolar macrophages by a 
bronchoalveolar lavage. 
4. Discussion 
This study shows that AMP is highly effective at inhibiting HIV-1 replication in  
chronically-infected MDM. Notably, this effect partially persists even after drug removal. These 
results are critical since MDM are an important cellular reservoir of HIV-1 infection, playing a critical 
role in HIV-1 transmission and dissemination throughout the body. There has been a recent 
resurgence of interest in the biology of monocyte subsets and MDM and their role in HIV-1 
pathogenesis, partly fueled by efforts to understand difficulties in achieving HIV-1 eradication. 
Indeed, MDM are resistant to the cytopathic effect of the virus and thus accumulate  
replication-competent HIV-1 for prolonged periods, even in patients receiving cART [35–37]. Due to 
the pivotal role of MDM in the pathogenesis of HIV-1 infection, drugs able to inhibit HIV-1 replication 
in this cellular reservoir are needed. Only protease inhibitors showed the unique capability to affect 
the production of mature infectious virions from long-lived HIV-1-infected MDM. 
In this study, we demonstrated that clinically-relevant concentrations of AMP (4 and 20 μM) 
efficiently affect HIV-1 production in HIV-1 chronically-infected MDM as attested by the substantial 
and stable inhibition of p24 release over time (up to Day 22 after treatment). We also found that a 
A
B
70
52.5
35
17.5
0
2° group 3° group
In
tr
a
c
e
ll
u
la
r
H
IV
-1
 p
2
4
/p
5
5
 r
a
ti
o
1° group
BaL 300 TCID50/ml
BaL 300 TCID50/ml + AMP 4 µL maintained
BaL 300 TCID50/ml + AMP 4 µL removed
2° group 3° group1° group
p24
p55
AMP 4 µL
HIV-1 BaL
300 TCID50/ml ++ + ++ +
+ + +
-
- - - +* - +*
++
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a bronchoalveolar lavage.
4. Discussion
This study shows that AMP is highly effective at inhibiting HIV-1 replication in
chronically-infected MDM. Not bly, this effect partially p sists even after drug removal. These results
are critical since MDM are an important cellular reservoir of HIV-1 infection, playing a criti al role in
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HIV-1 transmission and dissemination throughout the body. There has been a recent resurgence
of interest in the biology of monocyte subsets and MDM and their role in HIV-1 pathogenesis,
partly fueled by efforts to understand difficulties in achieving HIV-1 eradication. Indeed, MDM
are resistant to the cytopathic effect of the virus and thus accumulate replication-competent HIV-1
for prolonged periods, even in patients receiving cART [35–37]. Due to the pivotal role of MDM in
the pathogenesis of HIV-1 infection, drugs able to inhibit HIV-1 replication in this cellular reservoir
are needed. Only protease inhibitors showed the unique capability to affect the production of mature
infectious virions from long-lived HIV-1-infected MDM.
In this study, we demonstrated that clinically-relevant concentrations of AMP (4 and 20 µM)
efficiently affect HIV-1 production in HIV-1 chronically-infected MDM as attested by the substantial and
stable inhibition of p24 release over time (up to Day 22 after treatment). We also found that a long-term
anti-HIV-1 effect is partially maintained after drug removal with high concentrations of AMP in
chronically-infected MDM, suggesting a persistent intracellular activity of the drug. Furthermore,
a significant inhibition of infectivity was observed after drug removal, suggesting that the activity of
the drug determines the production of non-functional viral particles. Again, these results confirm that
AMP (and in general, protease inhibitors) may play a relevant role in inhibiting virus replication in
chronically-infected MDM.
AMP inhibits the cleavage of the HIV-1 p55 gag precursor protein to the p24 and p17 core
proteins [38–41], by interacting with high affinity to the substrate binding region of the mature viral
PR dimer [27]. Thus, virions released in the presence of the protease inhibitor contained p55, little or
no p24 and reduced RT. According to this, AMP (even after its removal) reduces the ratio of p24 on
p55, indicating an impaired maturation of viral particles. This was further confirmed by electron
microscopy, showing that AMP treatment determines the production of immature viral particles with
the doughnut-shaped morphology in contrast to mature virions containing condensed cone-shaped
cores observed in un-treated MDM. This is the first study addressing this issue in HIV-1-infected MDM,
characterized by a mechanism of HIV-1 release different from that observed in CD4+ T lymphocytes.
Again, the overall findings support the role AMP (and in general of this drug class) in controlling the
establishment and enlargement of HIV-1 infection in this cellular reservoir. These findings are also
important considering the results obtained in a recent study showing that immature virions produced
in the presence of protease inhibitors are incapable of efficiently completing entry, reverse transcription
and post-reverse transcription steps. This highlights the capability of protease inhibitors to block the
HIV-1 life cycle at multiple steps [42,43]. These results support the high efficacy of protease inhibitors
observed not only in cART, but also in simplification strategies. This is also clinically relevant in view
of the pivotal role of MDM in contributing to establishing HIV-1 persistence in different anatomical
compartments including the central nervous system.
Previous studies have shown that the pathway of HIV-1 particle morphogenesis can be different
in primary human macrophages compared to CD4+ T lymphocytes. Indeed, it has been shown that
HIV-1 can bud and accumulate within an intracellular vesicular compartment, mainly represented
by late endosomes [9,10,12,44]. This intracellular HIV-1 accumulation has been proposed to play
a pivotal role for pathogenesis and dissemination since HIV-1 can be retained in an infectious state for
prolonged periods of time inside macrophages and may be released in a delayed manner similar to the
secretion of exosomes. In this light, it can be hypothesized that AMP can be incorporated into viral
particles within late endosomes, thus favoring a prolonged release of immature and non-infectious
viral particles from chronically-infected MDM. The incorporation of AMP into viral particles within late
endosomes may also hamper the metabolism of the drug by the cytochrome P450 isoforms expressed in
monocytes/macrophages (CYP2E1 and CYP3A4), thus further contributing to persistent AMP activity.
Furthermore, a recent study has highlighted the contribution of tissue macrophages in establishing
a persistent infection despite successful cART [45]. In this light, the potent and prolonged
anti-HIV-1activity of amprenavir again supports the role of drugs acting at post-integrational steps in
controlling HIV-1 replication in chronically-infected MDM.
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Furthermore, recent studies have suggested HIV-1’s ability to establish a latent infection in
macrophages [46,47]. In particular, a recent study demonstrated the presence of the latent macrophage
reservoir in brains of SIV-infected ART-treated macaques [47]. The authors found that viral RNA in
brain tissue of suppressed macaques was undetectable, although viral DNA was detected in all animals.
In addition, they found that virus produced in latent macrophages is replication competent, suggesting
that latently-infected macrophages are capable of re-establishing productive infection upon treatment
interruption. The overall findings support the existence of latent reservoirs other than resting CD4+
T lymphocytes and underscore the importance of macrophages in developing strategies to eradicate
HIV [47]. In this light, the use of drugs acting at the post-integrational step appears critical in order to
prevent HIV-1 reactivation in latently-infected macrophages. This is critical also considering a previous
study showing that resting CD4+ T cells isolated from PI-treated patients compared to non-nucleoside
reverse transcriptase inhibitor (NNRTI)-treated patients showed a limited HIV-1 reactivation upon
T-cell stimulation [46]. This suggests that PI-based cART could be more efficient than NNRTI-based
cART in limiting HIV-1 reactivation in aviremic chronically-infected patients.
In conclusion, AMP shows high efficacy in blocking HIV-1 replication in MDM. This highlights
the role of this drug (and in general of protease inhibitors) in controlling the establishment and
enlargement of this important HIV-1 reservoir. Due to the role of MDM in disseminating HIV-1 in
different body compartments, this is also critical to efficiently hit HIV-1 replication in all anatomical
compartments where the virus hides and replicates.
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